Clinical Trial Update: PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating PET/CT-guided decisions to keep metastatic renal cell carcinoma patients free of systemic therapy. The study targets pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Jinling Hospital, China | Conditions: Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC) | Phase 2 | Status: RECRUITING